Table 1 Patients’ and tumor characteristics
Parameter | Intention to treat | Per protocol | ||||
|---|---|---|---|---|---|---|
Carb/TAX n = 20 | CDDP/5FU n = 31 | p-value | Carb/TAX n = 18 | CDDPs/5FU n = 26 | p-value | |
Median Age (IQR) | 62 (56–71) | 62 (55–72) | 0.875 | 61 (56–69) | 65 (57–72) | 0.489 |
Male | 13 (65%) | 20 (65%) | 1.000 | 13 (72%) | 16 (62%) | 0.531 |
T-stage | 0.143 | 0.103 | ||||
uT1 | 0 (0%) | 1 (3%) | 0 (0%) | 1 (4%) | ||
uT2 | 5 (25%) | 2 (6%) | 5 (28%) | 2 (8%) | ||
uT3 | 15 (75%) | 27 (87%) | 13 (72%) | 23 (88%) | ||
uT4 | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | ||
uN+ | 20 (100%) | 30 (97%) | 1.000 | 18 (100%) | 25 (96%) | 1.000 |
cM0 | 20 (100%) | 31 (100%) | 1.000 | 18 (100%) | 26 (100%) | 1.000 |
Grading | 1.000 | 0.765 | ||||
G1 | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | ||
G2 | 11 (58%) | 15 (52%) | 11 (61%) | 14 (56%) | ||
G3 | 8 (42%) | 13 (45%) | 7 (39%) | 11 (44%) | ||
Tumor extension (IQR) | 4 (2–6) | 5 (3–7) | 0.233 | 4 (2–6) | 5 (3–6) | 0.232 |